Perrigo Company, a leading global healthcare supplier that develops, manufactures and distributes OTC and prescription pharmaceuticals, nutritional products, API and consumer products, has agreed to settle its Hatch-Waxman litigation relating to Ofirmev (acetaminophen) injection brought by Cadence Pharmaceuticals, Inc. (Cadence).

Under the terms of the settlement, Perrigo can launch a generic version of Ofirmev (acetaminophen) injection on December 6, 2020, or earlier under certain circumstances. In addition, Perrigo has secured the right to be the sole authorized generic distributor should Cadence elect to launch an authorized generic product.

Ofirmev (acetaminophen) injection is administered intravenously as a single or repeated dose therapy for the reduction of fever and the treatment of mild to severe pain with or without adjunctive opioid analgesics. Ofirmev has annual sales of approximately $42 million, as measured by Wolters Kluwer.

Perrigo's chairman, president and CEO Joseph C Papa stated, "This settlement is another example of our long-term investment in extended product development. Perrigo continues its commitment to making quality healthcare more affordable for our customers."

From its beginnings as a packager of generic home remedies in 1887, Perrigo Company, based in Allegan, Michigan, has grown to become a leading global provider of quality, affordable healthcare products. The company develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products and active pharmaceutical ingredients (API) and is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. Perrigo's mission is to offer uncompromised "quality, affordable healthcare products", and it does so across a wide variety of product categories primarily in the United States, United Kingdom, Mexico, Israel and Australia, as well as certain other markets throughout the world, including Canada, China and Latin America.